Abstract
The T cell co-stimulatory molecule OX40 and its cognate ligand OX40L have attracted broad research interest as a therapeutic target in T cell-mediated diseases. Accumulating preclinical evidence highlights the therapeutic efficacy of both agonist and blockade of the OX40-OX40L interaction. Despite this progress, many questions about the immuno-modulator roles of OX40 on T cell function remain unanswered. In this review we summarize the impact of the OX40-OX40L interaction on T cell subsets, including Th1, Th2, Th9, Th17, Th22, Treg, Tfh, and CD8+ T cells, to gain a comprehensive understanding of anti-OX40 mAb-based therapies. The potential therapeutic application of the OX40-OX40L interaction in autoimmunity diseases and cancer immunotherapy are further discussed; OX40-OX40L blockade may ameliorate autoantigen-specific T cell responses and reduce immune activity in autoimmunity diseases. We also explore the rationale of targeting OX40-OX40L interactions in cancer immunotherapy. Ligation of OX40 with targeted agonist anti-OX40 mAbs conveys activating signals to T cells. When combined with other therapeutic treatments, such as anti-PD-1 or anti-CTLA-4 blockade, cytokines, chemotherapy, or radiotherapy, the anti-tumor activity of ...Continue Reading
Citations
Jul 18, 2020·Pharmaceutics·Lukas AmonChristian H K Lehmann
Jun 26, 2020·Vaccines·José Manuel RojasVerónica Martín
Jul 19, 2020·International Journal of Molecular Sciences·Cody BarbariRahul R Deshmukh
Aug 6, 2020·Frontiers in Immunology·Sonu BhaskarShelby Kutty
Aug 9, 2020·Frontiers in Bioengineering and Biotechnology·Chongyin HanFei Ling
Oct 22, 2020·Cancers·Piera FedericoBruno Daniele
Dec 12, 2020·RNA Biology·Yiwei ZhangYi Tian
Jan 14, 2021·Signal Transduction and Targeted Therapy·Xiaofei Zhou, Shao-Cong Sun
Nov 6, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin GutierrezIgnacio Melero
Jan 13, 2021·Cancers·Marc ArmengolGaël Roué
Feb 4, 2021·Cancers·Alessio Ugolini, Marianna Nuti
Feb 26, 2021·Nature Communications·Jenny MattssonBjörn Nilsson
Feb 23, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Emily De LombaerdeBruno G De Geest
Mar 13, 2021·Pharmaceutical Patent Analyst·Martin Perez-Santos
Mar 16, 2021·Frontiers in Immunology·Yun-Shiuan Olivia HsuChun-Bing Chen
Apr 27, 2021·Journal of Molecular Modeling·Wenchao TianWenyu Feng
Jun 18, 2021·Journal of Hepatocellular Carcinoma·Zhimei ZhouKangshun Zhu
Jul 20, 2021·Frontiers in Cell and Developmental Biology·Daniele E MascarelliMarcio C Bajgelman
Jul 15, 2021·Scientific Reports·Natalia Palazón-CarriónUNKNOWN Spanish Breast Cancer Group (GEICAM) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)
Aug 1, 2021·Molecular Immunology·Panpan FanDongchi Zhao
Aug 7, 2021·Frontiers in Pharmacology·Suqing LiuJinfeng Wu
Aug 6, 2021·International Immunopharmacology·Ning LiuMingxing Ma
Aug 10, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yu FuLing Zhang
Aug 29, 2021·Viruses·Roman P LabbéQasim A Rafiq
Aug 29, 2021·Current Oncology Reports·Andrea De GiglioFrancesco Gelsomino
Oct 5, 2021·Gene Therapy·Limin TianDeshan Li
Oct 22, 2021·Frontiers in Immunology·Ding-Ping ChenChing-Ping Tseng
Nov 4, 2021·Cancer Immunology, Immunotherapy : CII·Luya CaiWenfeng Li